Session » Metabolic and Crystal Arthropathies - Poster I: Clinical Practice

Date: Sunday, November 13, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 198

A Phase 2 Study to Evaluate the Efficacy and Safety of Febuxostat Extended- Versus Immediate-Release Formulations in Patients with Gout and Moderate Renal Impairment

9:00AM-11:00AM: Abstract Number: 199

A Phase 3 Study to Evaluate the Efficacy and Safety of Febuxostat Extended- Versus Immediate-Release Formulations in Patients with Gout

9:00AM-11:00AM: Abstract Number: 230

A Survey of Knowledge of Optimal Gout Management in an Academic Primary Care Setting

9:00AM-11:00AM: Abstract Number: 218

Accuracy of Humasens-Plus Point-of-Care Uric Acid Meter Using Capillary Blood Obtained By Fingertip Puncture

9:00AM-11:00AM: Abstract Number: 203

Allopurinol Dose Escalation and Mortality Among Patients with Gout: A National Propensity-Matched Cohort Study

9:00AM-11:00AM: Abstract Number: 201

Allopurinol Reduces the Risk of Myocardial Infarction (MI) in the Elderly: A Study of Medicare Claims

9:00AM-11:00AM: Abstract Number: 202

Allopurinol Use and the Risk of Ventricular Tachycardia in the US Elderly: A Study of Medicare Claims Data

9:00AM-11:00AM: Abstract Number: 214

Anakinra Compared to Prednisone on the Treatment of Acute CPPD Crystal Arthritis, a Randomized, Controlled, Double-Blind Study

9:00AM-11:00AM: Abstract Number: 215

Anakinra Is Effective and Well Tolerated in Medically Complex Patients Including Transplant Recipients with Gout

9:00AM-11:00AM: Abstract Number: 223

Clinical Predictors of Acute Gout Flares within Hospitalized Patients at a Tertiary Care Center in New York

9:00AM-11:00AM: Abstract Number: 209

Clinical Response of Tophus and Flares to Extended Use of Lesinurad in Combination with a Xanthine Oxidase Inhibitor in Patients with Gout

9:00AM-11:00AM: Abstract Number: 234

Coexistent Gout and Rheumatoid Arthritis: Comparison of Comorbidity, Autoantibodies, Disease Measures, and All-Cause Mortality

9:00AM-11:00AM: Abstract Number: 216

Colchicine Prescribing As a Parameter for QA/QI Process in Gout Care

9:00AM-11:00AM: Abstract Number: 226

Comparing the Burden of Illness of Patients with Tophaceous and Non-Tophaceous Gout in France, Germany, Italy, Spain, UK, and USA

9:00AM-11:00AM: Abstract Number: 235

Concurrence of Rheumatoid Arthritis and Calcium Pyrophosphate Deposition Disease: Description of a Cohort

9:00AM-11:00AM: Abstract Number: 208

Examination of Serum Uric Acid (sUA) Lowering and Safety with Extended Lesinurad + Allopurinol Treatment in Subjects with Gout

9:00AM-11:00AM: Abstract Number: 231

Impact of an Educational Program for the Management of Gout Directed to Primary Care Physicians

9:00AM-11:00AM: Abstract Number: 232

Impact of Gout Flare Prophylaxis and Urate-Lowering Therapy on Endothelial Function, Smooth Muscle Responsiveness and Markers of Inflammation: Results of a Prospective Observational Pilot Study

9:00AM-11:00AM: Abstract Number: 227

Inadequately Treated Chronic Gout As the Main Reason for Primary Gout Admission in an Urban Adult Population: Results of a Retrospective Cohort Study

9:00AM-11:00AM: Abstract Number: 207

Integrated Safety of Lesinurad, a Novel Uric Acid Reabsorption Inhibitor for the Treatment of Gout

9:00AM-11:00AM: Abstract Number: 233

New Cardiovascular Risk Factors Screening in Patients with Gout

9:00AM-11:00AM: Abstract Number: 224

Patient Perception of Gout Flares As a Measure of Outcome: Results from an International Study

9:00AM-11:00AM: Abstract Number: 225

Patterns of Joint Involvement in Gout Flares

9:00AM-11:00AM: Abstract Number: 212

Pegloticase Provides Clinical Benefit in Patients with Chronic Refractory Gout Who Did Not Meet the Clinical Trial Biochemical Definition of Response

9:00AM-11:00AM: Abstract Number: 192

Pharmacodynamic and Pharmacokinetic Study of Verinurad in Adult Male Subjects with Mild, Moderate, and Severe Renal Impairment: A Phase 1, Open-Label Study

9:00AM-11:00AM: Abstract Number: 196

Pharmacodynamic Effects and Safety of Verinurad in Combination with Allopurinol Versus Allopurinol Alone in Adults with Gout: A Phase 2a, Open-Label Study

9:00AM-11:00AM: Abstract Number: 197

Pharmacodynamic Effects and Safety of Verinurad in Combination with Febuxostat Versus Febuxostat Alone in Adults with Gout: A Phase 2a, Open-Label Study

9:00AM-11:00AM: Abstract Number: 195

Pharmacodynamics, Pharmacokinetics, and Safety of Verinurad in Combination with Febuxostat Versus Febuxostat Alone and Verinurad Alone in Japanese Adults with Gout or Asymptomatic Hyperuricemia: A Phase 2a, Open-Label Study

9:00AM-11:00AM: Abstract Number: 194

Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects with Gout

9:00AM-11:00AM: Abstract Number: 191

Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Febuxostat in Healthy Adult Male Subjects

9:00AM-11:00AM: Abstract Number: 190

Pharmacokinetics, Pharmacodynamics, and Tolerability of Verinurad, a Selective Uric Acid Reabsorption Inhibitor, in Healthy Adult Male Subjects

9:00AM-11:00AM: Abstract Number: 193

Pharmacokinetics, Pharmacodynamics, and Tolerability of Verinurad, a Selective Uric Acid Reabsorption Inhibitor, in Healthy Japanese Male Subjects

9:00AM-11:00AM: Abstract Number: 219

Presence of Monosodium Urate Crystals By Dual-Energy Computed Tomography in Gout Patients Treated with Allopurinol

9:00AM-11:00AM: Abstract Number: 213

Prophylaxis for Infusion Reactions to Pegloticase: An Analyis of Two Different Corticosteroid Pre-Infusion Regimens in US Community Rheumatology Practices

9:00AM-11:00AM: Abstract Number: 229

Relationship Between Patient and Disease Factors and Severity of Gout in a Real-World Population

9:00AM-11:00AM: Abstract Number: 206

Renal Safety of Lesinurad: A Pooled Analysis of Phase III and Extension Studies

9:00AM-11:00AM: Abstract Number: 222

Role of Synovial Biopsy in Diagnosis of Crystal Arthropathies

9:00AM-11:00AM: Abstract Number: 211

Safety and Efficacy of Febuxostat in Advanced CKD Patients with Hyperuricemia

9:00AM-11:00AM: Abstract Number: 205

Serum Uric Acid Lowering Treatment Appears Unnecessary during Hemodialysis

9:00AM-11:00AM: Abstract Number: 228

Sick Leave and Disability Pension in Working-Age Gout Patients before and after Diagnosis – a Population Based Case-Control Study

9:00AM-11:00AM: Abstract Number: 210

Skin Events with Febuxostat in Gout Patients and Previous Skin Reactions to Allopurinol. a Retrospective Review

9:00AM-11:00AM: Abstract Number: 217

The Effect of Regular Treatment on Disability in a Cohort of Patients with Gout.

9:00AM-11:00AM: Abstract Number: 204

The Safety and Efficacy of Allopurinol Dose Escalation in People with Gout, a Randomised Controlled Trial

9:00AM-11:00AM: Abstract Number: 200

The Safety and Efficacy of Benzbromarone in Gout in Aotearoa New Zealand

9:00AM-11:00AM: Abstract Number: 221

Ultrasound in Gout: The Clinical Application

9:00AM-11:00AM: Abstract Number: 220

Urate Lowering Therapy Regresses Ultrasound Abnormalities in Gout

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].